anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
To improve the intake of vegetables separately.SOLUTION: The essence of the present invention lies in that the selection basis of the intake of vegetables is the result of skin measurement. An intake-of-vegetables improvement system 100 includes at least an output unit 110 and a processor 150 when defining the present invention in such an aspect. The processor 150 controls the output unit 110 to display a sufficiency notification. In that time, the processor 150 refers to a skin state value of an individual. The sufficiency notification is delivered on the condition that the intake of vegetables of an individual is equal to or greater than a recommended intake of vegetables. An example of the skin state value is a skin carotenoid value.SELECTED DRAWING: Figure 7
The purpose of this study is to prevent the spread of S. aureus, a dangerous bacterium, within the operating room and between patients undergoing surgery. The investigators will combine several approaches in a "bundle" of activities to achieve this goal. The bundle will include removal of bacterial pathogens from patient skin sites before surgery, from provider hands before, during, and after surgery, from environmental surfaces before and after terminal cleaning, and from the injection ports of patient intravenous catheters. The investigators will use a new surveillance system to evaluate how well the bundle, and each component of the bundle, is working. Surveillance will identify S. aureus transmission events, and movement of S. aureus between reservoirs before, during, and after surgery (perioperative). Surveillance will map transmission events to identify actionable steps to improve the bundle. An infection control perioperative team will act on the surveillance reports to proactively address the action items, and to measure the effect of their efforts for the treatment group. The investigators will compare perioperative S. aureus transmission events for patients receiving the bundle to perioperative S. aureus transmission events for patients receiving usual care.
BACKGROUND: To develop and validate a peritumoral vascular and intratumoral radiomics model to improve pretreatment predictions for pathologic complete responses (pCRs) to neoadjuvant chemoradiotherapy (NAC) in patients with triple-negative breast cancer (TNBC).
METHODS: A total of 282 TNBC patients (93 in the primary cohort, 113 in the validation cohort, and 76 in The Cancer Imaging Archive [TCIA] cohort) were retrospectively included. The peritumoral vasculature on the maximum intensity projection (MIP) from pretreatment DCE-MRI was segmented by a Hessian matrix-based filter and then edited by a radiologist. Radiomics features were extracted from the tumor and peritumoral vasculature of the MIP images. The LASSO method was used for feature selection, and the k-nearest neighbor (k-NN) classifier was trained and validated to build a predictive model. The diagnostic performance was assessed using the ROC analysis.
RESULTS: One hundred of the 282 patient (35.5%) with TNBC achieved pCRs after NAC. In predicting pCRs, the combined peritumoral vascular and intratumoral model (fusion model) yields a maximum AUC of 0.82 (95% confidence interval [CI]: 0.75, 0.88) in the primary cohort, a maximum AUC of 0.67 (95% CI: 0.57, 0.76) in the internal validation cohort, and a maximum AUC of 0.65 (95% CI: 0.52, 0.78) in TCIA cohort. The fusion model showed improved performance over the intratumoral model and the peritumoral vascular model, but not significantly (p > 0.05).
CONCLUSION: This study suggested that combined peritumoral vascular and intratumoral radiomics model could provide a non-invasive tool to enable prediction of pCR in TNBC patients treated with NAC.
Factor IX Assays

When using an in vitro activated partial thromboplastin time (aPTT)-based one-stage clotting assay (OSA) for determining factor IX activity, plasma factor IX activity results can be affected by both the type of aPTT reagent, and the reference standard used in the assay. Higher inter-laboratory and inter-reagent variability in OSA results is observed at the lower factor IX activity levels (0.025 IU/mL). This is important to consider particularly when changing the laboratory and/or reagents used in the assay. It is recommended where possible to use the same laboratory (applicable to both, chromogenic or one-stage assays) for factor IX activity monitoring over time, particularly during the timeframe for corticosteroid treatment decision making, to minimize the impact of inter-laboratory variability [see Dosage and Administration (2.3)].

In clinical study 1 with BEQVEZ, silica-based OSA returned consistently higher values of factor IX activity compared to ellagic acid-based OSA and chromogenic substrate assay (CSA). Generally, values of the ellagic acid-based OSA aligned with values of CSA [see Table 4, Clinical Pharmacology (12.2)].

Based on clinical trials (central laboratory), the approximate conversion factor between a silica-based OSA and ellagic acid-based OSA/CSA is 2. For example, a factor IX activity level of 10 IU/dL using CSA calculates approximately to a level of 20 IU/dL using silica-based OSA. At low factor IX activity levels (0.05 IU/mL) the conversion factor is approximately 2.5.

Factor IX Inhibitors

Monitor patients through appropriate clinical observations and laboratory tests for the development of inhibitors to factor IX after BEQVEZ administration. Perform an assay that detects factor IX inhibitors if bleeding is not controlled, or plasma factor IX activity levels decrease.
The sham control (food safety education) consists of 10-weeks of targeted, brief interactions with parents when they come to pick up their children for a center-based early childcare program. The sessions will be twice per week.
Sodium amoxicilline preparation procedure. A suspension of amoxicillin is prepared in a solvent, containing isopropanol and a halogenous hydrocarbon of low molecular weight, like chloride of methylene, 1-2-dichloroethane, acetonitrilo or other. A primary or secondary aliphatic amine is adided, of low molecular weight. Representations of the mixture and an acetoacetamide-N-substitute sodium are reacted. The mixture of reaction at ambient temperature is shaken. The final product is isolated by filtration and eventually washed with a cetone. Application as antibiotic. (Machine-translation by Google Translate, not legally binding)
BACKGROUND: Animal and human health are seriously threatened by bacterial infections, which can lead to bacteremia and extremely high rates of morbidity and mortality. Recently, there have been reports indicating the involvement of exosomal circular RNAs (circRNAs) in a range of human disorders and tumor types. However, the role of exosomal circRNAs in bacterial infection remains elusive.
METHODS: We extracted and identified exosomes from the culture medium of PIEC cells infected with or without Glaesserella parasuis. RNA sequencing analysis was performed on the exosomes to screen and identify circRNAs (circHIF1α) associated with Glaesserella parasuis infection. PIEC cells were infected with Staphylococcus aureus or Streptococcus suis 2 to further determine whether exosome-derived circHIF1α was the crucial circHIF1α associated with bacterial infections. The transmission process of exosomes and their circHIF1α between cells was clarified via exosome tracing and co-culture assay. Moreover, the mechanism of circHIF1α being packaged into exosomes was explored, and the effects of exosomes and their circHIF1α on cell proliferation, DNA damage and cell cycle were analyzed. In addition, the binding mode and site of interacting proteins with circHIF1α were further determined. In vivo and in vitro, the role of exosomes and their circHIF1α in host resistance to bacterial infection was confirmed.
RESULTS: We first discovered a new circHIF1α that was very stable and detectable, encapsulated into exosomes by hnRNPA2B1, and whose expression in exosomes of bacterially infected PIEC cells significantly decreased. Additionally, exosomal circHIF1α reduced bacterial infection both in vitro and in vivo and suppressed the growth of reception cells. Mechanistically, the circHIF1α interacted with the KH domain of IGF2BP3 in an m6A-modified manner, which mediated DNA damage to arrest the cells at the G1/S phase through the interaction between the regulator of Chromosome Condensation 2 (RCC2) and γ-H2AX protein. Exosomal circHIF1α is a unique therapeutic target for bacterial infection since this work highlights its critical function in fighting bacterial infection.
Renal abscess (RA) is a collection of infective fluid in or around the renal parenchyma. It typically occurs in immunocompromised patients, including those with diabetes mellitus (DM), poor nutritional status, or steroid administration. We herein report a case of RA associated with DM in which hyperbaric oxygen (HBO2) therapy greatly contributed to the resolution of this disease. The patient was an 85-year-old man with poorly controlled type 2 DM. Contrast-enhanced computed tomography for postoperative follow-up of appendiceal cancer showed a mass lesion with poor contrast enhancement extending from the upper pole of the left kidney to the dorsal side. Therefore, a diagnosis of RA was established. The lesion was percutaneously punctured, and a drainage tube was placed. Antibiotics following sensitivity testing were administered. The catheter was removed six days after its placement. However, pus discharge continued from the catheter removal site, with persistent redness around the wound. Therefore, a lumbotomy incision for abscess drainage was performed on the 49th day. However, the pus discharge persisted, and we decided to perform HBO2 therapy, expecting decreases in bacterial proliferation, reduction in local edema, and improvement of host defense. HBO2 therapy for 90 min at two atmospheres absolute was performed ten times. The amount of pus discharge decreased, and redness improved from the fifth day after HBO2 therapy. One month after starting HBO2 therapy, the wound was closed, and the pus discharge resolved completely. Four years have passed since the HBO2 therapy, and there have been no symptomatic or imaging relapses of RA.
The invention discloses a high-bioavailability nintedanib nano lipid carrier and a preparation method thereof. The nano lipid carrier comprises nintedanib, a solid lipid material, a liquid lipid material, a surfactant and an absorption enhancer. The preparation scheme comprises the following steps: heating solid and liquid lipid in water bath at certain temperature, and stirring to melt. Adding surfactant, and stirring for 5 min. Adding nintedanib, and stirring for 1 hr to obtain oil phase containing medicine. Adding part or all of surfactant into water phase, preheating at the same temperature, and adding water phase into the above oil phase under stirring. And (5) after the probe is subjected to ultrasonic treatment, solidifying in ice-water bath to obtain the product. The Nintedanib nano lipid carrier prepared by the method has the advantages of simple scheme, no organic solvent, high drug loading rate, uniform particle size and particle size distribution, good stability, and capability of remarkably increasing the absorption of small intestinal epithelial cells to Nintedanib and effectively improving the in vivo bioavailability.
PURPOSE:To provide a solubilized cosmetic capable of compounding the chloride of glycyrrhetinic acid without causing the precipitation by chelating a zinc ion with a carboxylic acid and excellent in astringent and anti-inflammatory effects and stability. CONSTITUTION:The subject solubilized cosmetic contains (A) a compound capable of forming a zinc ion in an aq. soln. such as zinc sulfate, zinc chloride, zinc stearate and zinc p-phenolsulfonate, (B) a salt compound of glycyrrhetinic acid such as a di-potassium salt compound and an ammonium salt compound and (C) a carboxylic acid having a chelating coefficient to zinc ion of 10<-2>-10<-6> such as citric acid, tartaric acid, oxalic acid and histidine and its salt. The amount of A is 0.01-5wt.% (preferably 0.01-1.0wt.%), that of B is 0.01-1wt.% (preferably 0.5wt.%), that of C is 0.01-5wt.% and the C/A ratio is 1/1 to 20/1 (wt.mol. ratio).
BACKGROUND: The lipid-lowering and anti-inflammatory effects of statins and fibrates may ameliorate periodontitis. Patients with hyperlipidemia tend to have a worse periodontal status. This study assessed the association between the use of statins/fibrates and the incidence of chronic periodontitis in patients with hyperlipidemia in Taiwan.
METHODS: This retrospective cohort study enrolled patients newly diagnosed with hyperlipidemia between 2001 and 2012 from the 2000 Longitudinal Generation Tracking Database and followed them for 5 years. The study population was divided into four groups: statin monotherapy, fibrate monotherapy, combination therapy (both statins and fibrates), and control (neither statins nor fibrates). Each patient in the treatment group was matched at a ratio of 1:1 with a control. Chronic periodontitis risk was compared in the three study arms by using a Cox proportional hazard model.
RESULTS: Chronic periodontitis risk was reduced by 25.7% in the combination therapy group compared with the control group (adjusted hazard ratio [aHR], 0.743; 95% confidence interval (CI), 0.678-0.815). Low dose (<360 cumulative defined daily dose [cDDD]) and shorter duration (<2 years) of statin monotherapy seem to be associated with an increased risk of chronic periodontitis; high dose (≥720 cDDD/≥1080 cDDD) and longer duration (≥3 years) of statin/fibrate monotherapy may be correlated with a lower risk of periodontitis. Hydrophobic statin users had a lower chronic periodontitis risk than hydrophilic statin users.
CONCLUSION: Chronic periodontitis risk was lower in patients with hyperlipidemia on combination treatment with statins and fibrates, and the risk decreased when patients used statins or fibrates for >3 years.
OBJECTIVE: This inquiry endeavors to delineate the influence of PDIA3 on tumor-associated macrophages within the realm of colorectal malignancies, whilst elucidating the intrinsic biochemical pathways.
METHOD: Leveraging bioinformatics, we scrutinized the symbiosis between PDIA3, STAT3, and CD274. A xenograft model in immunodeficient murine served to assess PDIA3's impact on colorectal carcinogenesis. Further, Western blot analysis quantified the protein expression of PDIA3, p-STAT3, PD-1, XBP-1, assorted enzymes, and IL-6. Moreover, in vitro assays gauged SW480 cellular dynamics inclusive of migration, invasive potential, and proliferation.
RESULTS: Bioinformatics exploration exposed PDIA3's elevated presence in diverse cancers, with a marked expression in colorectal cancer, as per TCGA and GEO repositories. Correlative studies showed PDIA3 positively aligning with STAT3 and CD274, the latter also associated with monocyte-derived macrophages. Comparative analysis of colorectal neoplasms and normal colon samples unveiled heightened levels of PDIA3 markers which, when overexpressed in SW480 cells, escalated tumorigenicity and oncogenic behaviors, with a noted decrease upon PD-1 monoclonal antibody intervention.
CONCLUSIONS: PDIA3 augments the M2 polarization of tumor-associated macrophages via modulation of the STAT3/PD-1 cascade, thus invigorating the tumorous proliferation and dissemination in colorectal cancer. Such revelations position PDIA3 as an auspicious target for PD-1 blockade therapeutics, offering a promising foundation for rectifying colorectal carcinoma.
Patients eligible for an investigator initiated trial are given the standard PIS by email, and are also emailed a summary PIS and access to an online set of 10 video educational modules. They are then administered a demographic data collection form, the Quality of Informed Consent Questionnaire Parts A and B, and a user feedback survey form. They then present for their standard of care consent visit.
The present invention provides an oral medicinal liquid which belongs to the new medicines. Fresh rehmannia root which is one of the four largest pacification medicines in Henan province is used as raw materials. Constipation is a common disease and a frequently encountered disease; when people are constipated for a long term, presenility can be caused, and the disease symptoms of hemorrhoid, archoptoma, rectum cancer, etc. can be caused. The product of the present invention observed by three provincial level hospitals designated by Health Department of Henan province shows that the effective rate for the symptom of constipation due to heat and the symptom of deficient constipation respectively reaches 5% and 92.5%, and the curative effect of the present invention exceeds that of the similar products in China. A pharmacodynamics research shows that the product has the functions of shortening defecation time, increasing defecation amount, etc. A toxicological and clinical safety test shows that the product is safe and has no toxic side effect after being taken for a long term.
Brief Symptom Rating Scale is a rating scale which a clinician or researcher may use to measure psychiatric symptoms such as depression, anxiety, hallucinations and unusual behavior. Each symptom is rated 1-7 and depending on the version between a total of 18-24 symptoms are scored. The scale is the one of the oldest, widely used scales to measure psychotic symptoms and was first published in 1962.
BACKGROUND: Most gastric leiomyomas are asymptomatic and benign subepithelial tumors (SETs); however, some may increase in size or become symptomatic. Understanding their natural history is therefore important to their management. We investigated the natural history of histologically proven gastric leiomyomas.
METHODS: We retrospectively reviewed histologically proven gastric leiomyoma cases at a tertiary center. The baseline characteristics of these cases were analyzed, and those with a follow-up period of at least 12 months without immediate resection were evaluated. The primary outcome was the frequency of size increase of more than 25% during the follow-up period, and the secondary outcome was the histopathologic results in cases that underwent resection.
RESULTS: Among the 231 patients with histologically proven gastric leiomyomas, the most frequent location was the cardia (77.1%), and the median size was 3 cm (IQR 2-4 cm). Eighty-four cases were followed up over a median period of 50.8 months (IQR 27.2-91.3 months). During the follow-up period, tumor size increased in two cases (2.4%). Surgical results showed that one case was leiomyoma, and the other was leiomyosarcoma. Among the remaining cases without change in size, 15 underwent surgical resection (n = 10) or endoscopic resection (n = 5), and all cases were confirmed as leiomyoma.
CONCLUSIONS: Most gastric leiomyomas are benign SETs, and an increase in size is not frequent, even in large-sized cases. Close monitoring with routine follow-up without resection may be sufficient in cases of histologically proven gastric leiomyoma. However, in cases of ulceration or size increase, resection may be beneficial.
OBJECTIVE(S): Eccentric Chin Closure (ECC) exercise is a model designed to strengthen the suprahyoid muscles, aligned with the principles of eccentric exercise and the characteristics of these muscles. This study aimed to investigate the effects of the ECC exercise on submental muscle activation, muscle strength, dysphagia limit, perceived exertion, and pain, in comparison to the Shaker and Chin-Tuck Against Resistance (CTAR) exercises.
METHODS: In this parallel randomized controlled trial, for the initial assessment fifty-four healthy volunteers aged between 19-28 years with submental activations were recorded during the isotonic components of the Shaker, CTAR, and ECC exercises using surface electromyography. After the initial assessment, the volunteers were randomized to the Shaker, CTAR, and ECC exercise groups with 18 volunteers each group, and followed an 8-week exercise program. Maximum voluntary isometric contractions (MVC), muscle strength, dysphagia limit, perceived exertion, and pain were recorded at baseline in 4th week and 8th week.
RESULTS: At the initial assessment, lower submental muscle activation was observed during the Shaker exercise (p<0.05). Follow-up measurements demonstrated that the eight weeks of exercise was effective in increasing MVC activations and muscle strength across all groups. Considering the group*time effect, CTAR (0.36 ± 0.10) and ECC (0.40 ± 0.14) exercises were found to be more effective in increasing MVC than the Shaker (0.29 ± 0.19) exercise (F = 7.203, p<0.001), and the ECC (32.87 ± 6.55) exercise was more effective in improving muscle strength than both the Shaker (26.03 ± 5.86) and CTAR (27.95 ± 6.33) exercises (F = 6.786, p<0.001). Perceived exertion (F = 1.044, p = 0.388) and pain scores (F = 0.346, p = 0.846) showed statistically similar changes across the Shaker, CTAR, and ECC exercise groups.
CONCLUSION: The ECC exercise demonstrated similar effects on MVC to CTAR, but resulted in greater MVC than the Shaker exercise among healthy volunteers at 8 weeks. ECC was also more effective compared to Shaker and CTAR in terms of strength gain, with all exercises showing comparable levels of perceived exertion and pain.
When attempts to lose body fat mass frequently fail, breath acetone (BA) monitoring may assist fat mass loss during a low-carbohydrate diet as it can provide real-time body fat oxidation levels. This randomized controlled study aimed to evaluate the effectiveness of monitoring BA levels and providing feedback on fat oxidation during a three-week low-carbohydrate diet intervention. Forty-seven participants (mean age = 27.8 ± 4.4 years, 53.3% females, body mass index = 24.1 ± 3.4 kg m-2) were randomly assigned to three groups (1:1:1 ratio): daily BA assessment with a low-carbohydrate diet, body weight assessment (body scale (BS)) with a low-carbohydrate diet, and low-carbohydrate diet only. Primary outcome was the change in fat mass and secondary outcomes were the changes in body weight and body composition. Forty-five participants completed the study (compliance rate: 95.7%). Fat mass was significantly reduced in all three groups (allP< 0.05); however, the greatest reduction in fat mass was observed in the BA group compared to the BS (differences in changes in fat mass, -1.1 kg; 95% confidence interval: -2.3, -0.2;P= 0.040) and control (differences in changes in fat mass, -1.3 kg; 95% confidence interval: -2.1, -0.4;P= 0.013) groups. The BA group showed significantly greater reductions in body weight and visceral fat mass than the BS and control groups (allP< 0.05). In addition, the percent body fat and skeletal muscle mass were significantly reduced in both BA and BS groups (allP< 0.05). However, no significant differences were found in changes in body fat percentage and skeletal muscle mass between the study groups. Monitoring BA levels, which could have motivated participants to adhere more closely to the low-carbohydrate diet, to assess body fat oxidation rates may be an effective intervention for reducing body fat mass (compared to body weight assessment or control conditions). This approach could be beneficial for individuals seeking to manage body fat and prevent obesity.